tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Regeneron price target raised to $543 from $504 at BofA

BofA raised the firm’s price target on Regeneron (REGN) to $543 from $504 and keeps an Underperform rating on the shares. In a “strong Q2,” the only negatives were more delays in regulatory approval with Eylea HD formulation and odronextamab, though these “may be short-lived,” the analyst tells investors in a post-earnings note. The firm has felt consensus forecasts could be at risk from faster-than-expected Eylea erosion, but Friday’s performance was “encouraging,” the analyst added.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1